Expression of PD-L1 by immunohistochemistry in tumor samples was approved by the US Food and Drug Administration (FDA) to be the criteria for the use of some ICIs, e.g., the indication for pembrolizumab in treating metastatic NSCLC. This evidence concerns the gene CD274 and neoplasm.